See more : Bitcoin Generation Inc. (BTGN) Income Statement Analysis – Financial Results
Complete financial analysis of Sensorion SA (ALSEN.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sensorion SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Marwyn Value Investors Limited (MVI.L) Income Statement Analysis – Financial Results
- Bharat Forge Limited (BHARATFORG.NS) Income Statement Analysis – Financial Results
- PT Indopoly Swakarsa Industry Tbk (IPOL.JK) Income Statement Analysis – Financial Results
- China Overseas Land & Investment Limited (CAOVY) Income Statement Analysis – Financial Results
- Imperio Alternatywna Spolka Inwestycyjna S.A. (IMP.WA) Income Statement Analysis – Financial Results
Sensorion SA (ALSEN.PA)
About Sensorion SA
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.74M | 4.93M | 4.26M | 2.35M | 2.46M | 2.23M | 1.93M | 17.50K | 157.51K | 231.57K | 356.53K | 231.69K | 21.00 |
| Cost of Revenue | 955.20K | 770.48K | 513.51K | 415.16K | 303.85K | 347.11K | 385.36K | 6.78M | 3.70M | 0.00 | 989.47K | 0.00 | 49.69K |
| Gross Profit | 3.79M | 4.16M | 3.75M | 1.94M | 2.15M | 1.88M | 1.55M | -6.76M | -3.54M | 231.57K | -632.93K | 231.69K | -49.67K |
| Gross Profit Ratio | 79.86% | 84.38% | 87.96% | 82.35% | 87.63% | 84.44% | 80.08% | -38,622.41% | -2,246.43% | 100.00% | -177.52% | 100.00% | -236,514.29% |
| Research & Development | 22.76M | 22.27M | 14.17M | 7.39M | 9.91M | 11.91M | 7.87M | 5.66M | 3.55M | 2.27M | 1.23M | 711.35K | 0.00 |
| General & Administrative | 97.40K | 130.63K | 105.99K | 99.44K | 93.33K | 2.52M | 3.67M | 872.71K | 0.00 | 28.85K | 25.24K | 13.27K | 0.00 |
| Selling & Marketing | 0.00 | 25.99K | 184.29K | 3.38M | 3.01M | 288.64K | 173.38K | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 97.40K | 5.06M | 4.67M | 3.48M | 3.11M | 2.81M | 3.84M | 1.91M | 1.58M | 28.85K | 25.24K | 13.27K | 0.00 |
| Other Expenses | 4.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.65M | 136.74K | 763.32K | 592.52K | 478.74K | 593.93K |
| Operating Expenses | 27.05M | 27.33M | 18.84M | 10.87M | 13.01M | 14.46M | 11.45M | 2.37M | 1.80M | 3.06M | 1.85M | 1.20M | 593.93K |
| Cost & Expenses | 27.05M | 28.10M | 19.35M | 11.29M | 13.32M | 14.46M | 11.45M | 9.15M | 5.50M | 3.06M | 1.85M | 1.20M | 643.62K |
| Interest Income | 718.11K | 95.57K | 53.55K | 43.43K | 39.04K | 124.25K | 170.38K | 59.19K | 2.04K | 2.14K | 5.32K | 3.49K | 818.00 |
| Interest Expense | 213.70K | 205.35K | 188.73K | 152.67K | 1.34M | 158.62K | 232.84K | 6.13K | 29.40K | 219.27K | 161.42K | 17.98K | 0.00 |
| Depreciation & Amortization | 266.19K | 770.48K | 513.51K | 415.16K | 303.85K | 347.11K | 385.36K | 351.20K | 128.02K | 69.68K | 21.56K | 5.33K | 3.69K |
| EBITDA | -22.31M | -22.44M | -14.61M | -8.85M | -10.67M | -11.92M | -9.29M | -8.72M | -5.19M | -2.90M | -1.46M | -964.03K | -639.92K |
| EBITDA Ratio | -470.45% | -554.04% | -441.79% | -462.35% | -529.74% | -534.49% | -480.21% | -51,307.49% | -3,297.78% | -1,205.70% | -410.56% | -416.08% | -3,047,219.05% |
| Operating Income | -22.31M | -28.10M | -19.35M | -11.29M | -13.32M | -12.31M | -9.61M | -9.11M | -5.32M | -2.86M | -1.49M | -972.85K | -643.60K |
| Operating Income Ratio | -470.38% | -569.66% | -453.84% | -480.00% | -542.11% | -551.69% | -496.61% | -52,039.05% | -3,379.05% | -1,236.72% | -418.10% | -419.89% | -3,064,766.67% |
| Total Other Income/Expenses | 544.22K | -3.96M | -3.12M | -1.94M | -3.74M | -124.25K | -170.38K | 32.11K | -13.40K | -112.71K | 112.95K | -14.49K | 818.00 |
| Income Before Tax | -21.77M | -27.09M | -18.14M | -10.82M | -14.55M | -12.35M | -9.69M | -9.07M | -5.34M | -3.08M | -1.65M | -987.33K | -642.78K |
| Income Before Tax Ratio | -458.91% | -549.14% | -425.50% | -460.20% | -592.38% | -553.70% | -500.72% | -51,855.57% | -3,387.56% | -1,330.48% | -461.88% | -426.14% | -3,060,871.43% |
| Income Tax Expense | 296.99K | -3.88M | -3.01M | -1.85M | -2.46M | -2.22M | -1.89M | 1.66M | 1.06M | 217.13K | 156.10K | 14.49K | -155.51K |
| Net Income | -22.06M | -23.21M | -15.14M | -8.98M | -12.10M | -12.35M | -9.69M | -7.41M | -4.27M | -3.08M | -1.65M | -987.33K | -487.16K |
| Net Income Ratio | -465.17% | -470.42% | -355.01% | -381.71% | -492.38% | -553.70% | -500.72% | -42,357.04% | -2,711.52% | -1,330.48% | -461.88% | -426.14% | -2,319,823.81% |
| EPS | -0.17 | -0.29 | -0.19 | -0.15 | -0.65 | -1.08 | -1.34 | -1.09 | -1.00 | -0.94 | -0.50 | -0.30 | -0.15 |
| EPS Diluted | -0.17 | -0.29 | -0.19 | -0.15 | -0.65 | -1.08 | -1.34 | -1.09 | -1.00 | -0.94 | -0.50 | -0.30 | -0.15 |
| Weighted Avg Shares Out | 133.42M | 79.84M | 79.69M | 60.76M | 18.65M | 11.41M | 7.21M | 6.81M | 4.27M | 3.26M | 3.26M | 3.26M | 3.26M |
| Weighted Avg Shares Out (Dil) | 133.42M | 79.84M | 79.69M | 60.76M | 18.65M | 11.41M | 7.21M | 6.81M | 4.27M | 3.26M | 3.26M | 3.26M | 3.26M |
Source: https://incomestatements.info
Category: Stock Reports